Allergan, Inc.

Joan-En Chang-Lin

James Nienyuan Chang

Rhett M Schiffman

Chin-Ming Chang

R Scott Jordan

Patrick Michael Hughes

Thomas C Malone

Thierry Nivaggioli

Joseph G Vehige

Peter A Simmons

Jeffrey L Edelman

Jane-Guo Shiah

Lon T Spada

Wendy M Blanda

Gerald W De Vries

Gerald Woodrow DeVries

Orest Olejnik

Jane Guo Shiah

Jeffery L Edelman

Michael R Robinson

James A Burke

Scott M Whitcup

Devin F Welty

Patric M Hughes

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Biodegradable intravitreal tyrosine kinase implants

Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.

Ophthalmic compositions and methods for treating eyes

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Enhanced bimatoprost ophthalmic solution

Membrane transporter-targeted therapeutic agents and methods of making and using the same.

Compositions and methods for the intraocular transport of therapeutic agents

A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.

Method for determining optimum intraocular locations for drug delivery systems

Growing community of inventors

Tustin, CA, United States of America

Joan-En Chang-Lin